{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:24:39Z","timestamp":1789619079689,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073924"],"award-info":[{"award-number":["82073924"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Ezetimibe (EZE) is a selective cholesterol absorption inhibitor. Hepatic impairment significantly increases the systemic exposure of EZE and its main active phenolic glucuronide, EZE-Ph. Although changes in efflux transporter activity partly explain the changes in EZE-Ph pharmacokinetics, the causes of the changes to EZE and the effects of the administration route on EZE-Ph remain unclear. A carbon tetrachloride (CCl4)-induced hepatic failure rat model was combined with in vitro experiments to explore altered EZE and EZE-Ph disposition caused by hepatic impairment. The plasma exposure of EZE and EZE-Ph increased by 11.1- and 4.4-fold in CCl4-induced rats following an oral administration of 10 mg\/kg EZE, and by 2.1- and 16.4-fold after an intravenous injection. The conversion of EZE to EZE-Ph decreased concentration-dependently in CCl4-induced rat liver S9 fractions, but no change was observed in the intestinal metabolism. EZE-Ph was a substrate for multiple efflux and uptake transporters, unlike EZE. In contrast to efflux transporters, no difference was seen in the hepatic uptake of EZE-Ph between control and CCl4-induced rats. However, bile acids that accumulated due to liver injury inhibited the uptake of EZE-Ph by organic anion transporting polypeptides (OATPs) (glycochenodeoxycholic acid and taurochenodeoxycholic acid had IC50 values of 15.1 and 7.94 \u03bcM in OATP1B3-overexpressed cells). In conclusion, the increased plasma exposure of the parent drug EZE during hepatic dysfunction was attributed to decreased hepatic glucuronide conjugation, whereas the increased exposure of the metabolite EZE-Ph was mainly related to transporter activity, particularly the inhibitory effects of bile acids on OATPs after oral administration.<\/jats:p>","DOI":"10.3390\/pharmaceutics14122743","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T02:17:57Z","timestamp":1670465877000},"page":"2743","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Changes in Disposition of Ezetimibe and Its Active Metabolites Induced by Impaired Hepatic Function: The Influence of Enzyme and Transporter Activities"],"prefix":"10.3390","volume":"14","author":[{"given":"Ningjie","family":"Xie","sequence":"first","affiliation":[{"name":"University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China"},{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China"},{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Qin","sequence":"additional","affiliation":[{"name":"Beijing Tianheng Pharmaceutical Research Institute Co., Ltd., No. 93, Zone 6, Doudian Village, Beijing 102433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitao","family":"Guo","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xue","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Hu","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China"},{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China"},{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"ref_1","unstructured":"Roser, H.R.a.M. (2019, December 01). Causes of Death. Available online: https:\/\/ourworldindata.org\/causes-of-death."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and Management of Hepatocellular Carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1073274817729245","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"24","author":"Massarweh","year":"2017","journal-title":"Cancer Control"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: Immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/hep.20528","article-title":"AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings","volume":"40","author":"Sherman","year":"2004","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40262-015-0238-6","article-title":"Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers","volume":"54","author":"Nasser","year":"2015","journal-title":"Clin. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03602532.2016.1271807","article-title":"Drug metabolism and liver disease: A drug-gene-environment interaction","volume":"49","author":"Zgheib","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450\u2014mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00535-015-1148-y","article-title":"The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease","volume":"51","author":"Okushin","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1665-2681(19)31740-5","article-title":"Reversibility of liver fibrosis","volume":"8","author":"Ramachandran","year":"2009","journal-title":"Ann. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/(SICI)1099-081X(199711)18:8<717::AID-BDD54>3.0.CO;2-U","article-title":"The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats","volume":"18","author":"Yamamura","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Piotrowska-Kempisty, H., Nowicki, M., Jodynis-Liebert, J., Kurpik, M., Ewertowska, M., Adamska, T., Oszmianski, J., and Kujawska, M. (2020). Assessment of Hepatoprotective Effect of Chokeberry Juice in Rats Treated Chronically with Carbon Tetrachloride. Molecules, 25.","DOI":"10.3390\/molecules25061268"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-1-0716-1382-5_23","article-title":"Mouse Models of Liver Fibrosis","volume":"2299","author":"Ravichandra","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.lfs.2005.09.025","article-title":"Selective protection of curcumin against carbon tetrachloride-induced inactivation of hepatic cytochrome P450 isozymes in rats","volume":"78","author":"Sugiyama","year":"2006","journal-title":"Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1124\/dmd.31.4.482","article-title":"Multiple alterations of canalicular membrane transport activities in rats with CCl(4)-induced hepatic injury","volume":"31","author":"Song","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/bdd.563","article-title":"Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride","volume":"28","author":"Khemawoot","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jps.22286","article-title":"Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity","volume":"100","author":"Taguchi","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41551-018-0279-x","article-title":"Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs","volume":"2","author":"Golder","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.phrs.2017.09.019","article-title":"Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies","volume":"128","author":"Yuan","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Luo, L., Aubrecht, J., Li, D., Warner, R.L., Johnson, K.J., Kenny, J., and Colangelo, J.L. (2018). Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193824"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1742-4658.2007.05670.x","article-title":"Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33","volume":"274","author":"Barre","year":"2007","journal-title":"FEBS J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0960-0760(99)00088-6","article-title":"Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7","volume":"70","author":"Gall","year":"1999","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: Molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/dmd.121.000643","article-title":"Molecular Regulation of Bile Acid Homeostasis","volume":"50","author":"Choudhuri","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Lisnock","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.32.3.314","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"Farley","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/dmd.30.4.430","article-title":"Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects","volume":"30","author":"Patrick","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FPC.0b013e3282fe9a2c","article-title":"Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1","volume":"18","author":"Oswald","year":"2008","journal-title":"Pharm. Genom."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clpt.2005.11.004","article-title":"Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans","volume":"79","author":"Oswald","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","unstructured":"(2002, October 25). Zetia Clinical Pharmacology Biopharmaceutic Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21445_Zetia_biopharmr_P2.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1083\/jcb.43.3.506","article-title":"High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study","volume":"43","author":"Berry","year":"1969","journal-title":"J. Cell. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0887-2333(98)00055-1","article-title":"Optimizing preincubation conditions for precision-cut rat kidney and liver tissue slices: Effect of culture media and antioxidants","volume":"12","author":"Obatomi","year":"1998","journal-title":"Toxicol. In Vitro"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"pdb.prot5439","DOI":"10.1101\/pdb.prot5439","article-title":"Purification of RNA using TRIzol (TRI reagent)","volume":"2010","author":"Rio","year":"2010","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/tx800225q","article-title":"Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: Quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry","volume":"21","author":"Yang","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0300-483X(92)90004-X","article-title":"Individual serum bile acids as early indicators of carbon tetrachloride- and chloroform-induced liver injury","volume":"75","author":"Bai","year":"1992","journal-title":"Toxicology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14634","DOI":"10.3390\/ijms131114634","article-title":"Radix Paeoniae Rubra and Radix Paeoniae Alba Attenuate CCl4-Induced Acute Liver Injury: An Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) Based Metabolomic Approach for the Pharmacodynamic Study of Traditional Chinese Medicines (TCMs)","volume":"13","author":"Wang","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/acs.jproteome.0c00852","article-title":"Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease","volume":"20","author":"Sang","year":"2021","journal-title":"J. Proteome Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008469-199309000-00006","article-title":"Bile acid inhibition of xenobiotic-metabolizing enzymes is a factor in the mechanism of colon carcinogenesis: Tests of aspects of the concept with glucuronosyltransferase","volume":"2","author":"Schneider","year":"1993","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/SLC21 family: Phylogenetic classification as OATP\/SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflug. Arch."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.108.026146","article-title":"Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2","volume":"37","author":"Vlaming","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/12\/2743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:36:12Z","timestamp":1760146572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/12\/2743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["pharmaceutics14122743"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14122743","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]}}}